source
- AstraZeneca signs $40 million AI drug-discovery deal with insitro as inVIOs reports Phase 1 tumor successAstraZeneca announced a partnership with insitro, a California AI‑driven drug discovery firm, agreeing to pay $40 million upfront for collaboration. The agreement aims to combine AstraZeneca’s the…
- Estuary Biotherapeutics raises $103M to advance gene therapies for polycystic kidney diseaseEstuary Biotherapeutics announced it has exited stealth mode after securing $103 million in financing to move two gene‑therapy candidates into clinical testing for autosomal dominant polycystic kid…